Our present work characterized the role of hormone-mediated signal transduction pathways in regulating hepatic reduced glutathione (GSH) synthesis. Cholera toxin, dibutyryl cAMP (DBcAMP), and glucagon inhibited GSH synthesis in cultured hepatocytes by 25-43%. Cellular cAMP levels exhibited a lower threshold for stimulation of the GSH efflux than inhibition of its synthesis. The effect of DBcAMP was independent of the type of sulfur amino acid precursor and cellular ATP levels and unassociated with increased GSH mixed disulfide formation or altered GSH/oxidized glutathione ratio. In liver cytosols, addition of DBcAMP and cAMP-dependent protein kinase (A-kinase) inhibited GSH synthesis from substrates (cysteine, ATP, glutamate, and glycine) by -20% which was prevented by the A-kinase inhibitor. However, if only substrates of the second step in GSH synthesis were used (y-glutamylcysteine, glycine, and ATP), DBcAMP and A-kinase exerted no inhibitory effect. Phenylephrine, vasopressin, and phorbol ester also inhibited GSH synthesis in cultured cells by -20%, and depleted cell GSH independent of the type of sulfur amino acid precursor. Cellular cysteine level was unchanged despite the significant fall in GSH after glucagon or phenylephrine treatment. Pretreatment with either staurosporine, C-kinase inhibitor, or calmidazolium, a calmodulin inhibitor, partially prevented but, together, completely prevented the inhibitory effect of phenylephrine. The same combination had no effect on the inhibitory effect of glucagon. The effects of hormones were confirmed in both the intact perfused liver and after in vivo administration. Thus, two classes of hormones acting through distinct signal transduction pathways may down-regulate hepatic GSH synthesis by phosphorylation of y-glutamylcysteine synthetase. (J. Clin. Invest. 1991. 88:260-269.) Key words:
Introduction
Reduced glutathione (GSH) is a tripeptide, y-glutamylcysteinylglycine, found in all mammalian tissues but with especially high hepatic levels. GSH defends against many toxins and free Cell culture preparation Hepatocytes were isolated aseptically according to the method ofMoldeus et al. (12) . Initial cell viability was 2 90% as determined by 0.2% trypan blue exclusion. The basic medium was DME/F12, high glucose, containing 10% fetal bovine serum, insulin (1 gg/ml) and hydrocortisone (50 nM). 1.5-2 X 106 cells in 5 ml ofbasic medium were plated on 60 X 15-mm dishes precoated with rat tail collagen, incubated at 370C in 5% C02, 95% air. 2-3 h after plating medium was changed to basic medium omitting serum and to remove dead, unattached cells. Cell attachment averaged -50%.
GSH synthesis experiments in cultured hepatocytes 24 h after plating, cells were treated with the agent of interest (or vehicle) for variable periods oftime. In addition, cellular GSH was acutely depleted by diethyl maleate (DEM, 0.2 mM) which forms a thioether conjugate with GSH. 30 min after DEM treatment, cells were washed free of DEM and replenished with fresh SAF medium supplemented with excess GSH precursor, methionine (1 mM), and the agent ofinterest. Total GSH (cell + medium) was measured by the GSH recycling assay of Tietze (13) at time 0, 30, 60 , and 120 min after this change in medium. At the end of the incubation period, medium was saved and cells were washed twice with Krebs buffer, pH 7.4 (5 ml), detached by trypsin-EDTA (0.05%, 0.02%, respectively) for cell counting by both cell counter (Coulter Corp., Hialeah, FL) and hemocytometer and viability determination which was 2 90% by trypan blue exclusion. Cellular GSH was extracted with 10% trichloroacetic acid and measured in the supernatant samples after centrifugation at 13,000 gin a microfuge (Beckman Instruments, Inc., Fullerton, CA) for 1 min to remove the denatured proteins. For each condition and time point, mean values from triplicate plates were used. The rate ofaccumulation oftotal GSH after acute depletion with DEM was the GSH synthesis rate.
GSH synthesis using in situ liver perfusion model
The design, method, and apparatus for in situ liver perfusions were previously described (14) . To measure GSH synthesis, rats were treated with DEM (0.4 ml/kg i.p.) to deplete GSH 1 h before in situ liver perfusion. During liver perfusion, excess amounts of precursors for GSH synthesis (methionine 1 mM, serine 1 mM, glycine 10 mM, and glutamate 5 mM) were added to Krebs-Ringer buffer. The effects of glucagon (50 nM) or phenylephrine (10 MM) were studied by adding them to the buffer. Serial liver biopsies (0.1-0.2 g) were taken at times 0 (just before start ofperfusion with precursor-rich buffer), 15, 30 , and 45 min for GSH assay. For each in situ liver perfusion, the bile duct was cannulated with PE-1O tubing (Clay Adams, Parsippany, NJ) and bile was collected after a retrograde biliary infusion of20 umol/kg acivicin, an irreversible inhibitor of -y-glutamyl transpeptidase. During perfusions (45 min), adding taurocholate (15 MM) to the buffer maintained bile flow. The perfusion rates were 4.56+0.15 ml/min -g liver, and the 02 uptakes were 2.23±0.12 Mmol/min . g liver (mean±SEM, n = 15).
These values agree with previous reports (14) , and they were similar in the two treatment groups compared to controls. Perfuisate samples were taken at the end of 5-min intervals. Bile samples were collected continuously every 15 min. Liver, perfuisate, and bile GSH were measured by the method of Tietze ( 13) . The rate of accumulation of total GSH (liver, bile, and perfusate) was the GSH synthesis rate. Cell lysis was monitored by measuring glutathione S-transferase in the perfusates (15) ; no lysis was detected up to 45 mn.
GSH synthesis experiments using monochlorobimane Monochlorobimane (mBCl) forms a fluorescent adduct with GSH. The reaction, catalyzed by GSH S-transferase, is very sensitive and specific for GSH. Measuring the adduct by fluorimeter in intact hepatocytes or cell free conditions with liver cytosol agrees with synthesis rates determined by the method of Tietze (16) .
Preparing liver cytosol and using mBCI to determine GSH synthesis rates in liver cytosols were previously described (16 Effects ofDBcAMP. All rats were treated first with DEM (0.4 ml/kg i.p.). 15 min later either DBcAMP (25 mg/ml saline) plus theophylline (10 mg/ml saline) mixture or saline was given intraperitoneally (0.2 ml/100 g); 1 h later the rats were killed and GSH synthesis rates in liver cytosol in the presence of precursors cysteine, glutamate, and glycine were measured using mBCI.
Effects ofphenylephrineandglucagon. Underpentobarbital anesthesia (50 mg/kg i.p.), a carotid artery and a jugular vein were cannulated with PE-50 polyethylene tubing. Starting at time zero, blood samples (0.25-0.4 ml) were obtained at 5-10-min intervals from the carotid artery for measurement of plasma GSH and glucose levels. Treatment groups received either phenylephrine (50 nmol/min) or glucagon (52 pmol/min, the dose that was previously established (10) to raise plasma glucose by 64% over baseline after 15 min of infusion). The paired control group received 0.9% NaCl throughout. Infusions were 52 Ml/ min by infusion pumps (Harvard Apparatus, S. Natick, MA) in all groups and total infusion times were 15 min (phenylephrine) and 30 min (glucagon). The blood taken was replaced by NaCl or phenylephrine/glucagon solutions. The animals' temperatures stayed between 37 and 38°C using a heating lamp. The animals were then exsanguinated and the livers homogenized for determination of GSH by the method of Tietze (13) and processed to prepare liver cytosol (16) . GSH synthesis rates in liver cytosol were measured using mBCI. Plasma GSH level was measured by the method of Adams et al. (17) . Briefly, 0.2 ml ofeach blood sample was added immediately to 0.2 ml of 10 mM DTNB in phosphate-buffered saline (pH 7.5) containing 12.5 mM Na4EDTA. Aftergentle mixing, the samples were centrifuged for 1 min at 15,850 g in a Beckman Instruments, Inc. Microfuge E to remove blood cells. This did not cause detectable hemolysis. Total GSH concentration in the supernatant was measured by the method of Tietze (13) . Plasma GSH concentration was calculated from the measured concentration and the hematocrit determined in heparinized capillary tubes.
Glucose level was measured from the same supernatant samples by the Sigma Diagnostic Glucose (Trinder) reagent. Plasma glucose level was calculated from the measured glucose level and the hematocrit. Alanine aminotransferase (ALT) level was measured from the terminal plasma samples of the phenylephrine-treated group and the controls by the Sigma Diagnostic ALT 50 kit.
Hormonal Regulation ofHepatic Reduced Glutathione Synthesis

Measurement ofefflux in cultured cells
All experiments were carried out 20-24 h after plating. The medium was aspirated, and cells were washed twice with Krebs-Henseleit buffer, supplemented with 12.5 mM Hepes (pH 7.4), then incubated with 5 ml of Krebs buffer at 370C in 5% CO2 for 90 min. GSH was assayed on 500-,u aliquots of supernatant at 5, 30, 60, and 90 min by the method ofTietze (13) . The accumulation ofGSH in the supernatant was linear over 90 min; thus efflux rates were calculated by linear regression. In parallel experiments, cell lysis during the course ofincubation was estimated by measuring the release of glutathione S-transferase from the cytosol into the supernatant as a fraction oftotal cellular enzyme activity (15) . Cell lysis was < 5% and did not increase during 90-min incubation. Cells were then processed as described in the synthesis experiments for cell count and GSH measurements. To measure cellular glutathione S-transferase content, cells were scraped offthe plates with a rubber policeman and treated with 10% Triton X-100 in phosphate buffer saline (1:1, vol/vol). After centrifugation in a microfuge, enzyme activity was measured as previously described (15) .
In addition to measuring GSH efflux in Krebs buffer, estimates of GSH efflux were obtained using the percentage of total GSH accumulated in the medium after 2-h incubation during the synthesis experiment in the presence of culture medium (see above).
Molecularforms ofGSH
Cultured hepatocytes were incubated with DBcAMP (0.1 mM) for 4 h and cells were treated as described under the synthesis experiments. Cell-free extract after treatment with 10% trichloroacetic acid was derivatized and analyzed by high-performance liquid chromatography (HPLC) according to the method of Reed et al. (18) to determine the molecular forms of glutathione.
Cellular ATP content
Cultured hepatocytes were incubated with DBcAMP (0.1 mM) or vehicle overnight and cellular ATP levels were determined by HPLC according to the method of Jones (19 
Cysteine concentration
Hepatocytes were plated in SAF medium supplemented with methionine (1 mM) and incubated with glucagon (300 nM), phenylephrine (0.1 mM) or vehicle overnight. Cells (-106 per plate) were collected by detaching with trypsin-EDTA (0.05%, 0.02%, respectively), then centrifuged in a microfuge for 30 s to remove the trypsin-EDTA solution. Cells were then treated with 5% perchloric acid to precipitate the proteins and centrifuged for 1 min in a microfuge, and supernatant cysteine levels were determined according to the method ofGaitonde (20) .
Cysteine levels were measured in liver homogenates at the end ofin situ liver perfusion according to the method of Gaitonde (20 
Results
Effects ofhormones on GSH synthesis and efflux in cultured hepatocytes Cyclic AMP-dependent factors. Cultured hepatocytes were incubated with DBcAMP (0.1 mM) or cholera toxin (CT, 2 ng/ ml) and cell GSH levels and GSH efflux were measured after variable periods of time. Cell GSH level fell significantly (77% of control) after 2 h of incubation with DBcAMP, and fell further to 64% of control after 21 h of incubation ( Fig. 1 A) . However, cell GSH level was maintained up to 4 h of incubation with CT but fell after overnight incubation. The fall in cell GSH after 2-4 h of incubation with DBcAMP cannot be explained by increased GSH efflux alone since both DBcAMP and CT stimulated GSH efflux to similar extents ( Fig. 1 B) .
This suggested GSH synthesis may be impaired in the presence of DBcAMP. Table I shows maximum inhibition occurred with 100 AM DBcAMP and no effect occurred with 10 AM. On the other hand, the dose required to stimulate GSH efflux was 1 MM, with maximum effect at 10 MM. Therefore, the thresholds of these two responses differ: a lower threshold for stimulation of GSH efflux and a higher threshold for inhibition of GSH synthesis. This phenomenon was further demonstrated with two other cAMP-dependent agents, CT and glucagon (Table II) . The doses that stimulated GSH efflux (CT, 0.2 ng/ml; glucagon, 10 nM) were 1/Oth the doses that inhibited GSH synthesis (CT, 2 ng/ml; glucagon, 140 nM). The corresponding cellular cAMP levels after treatment with CT or glucagon were measured by RIA (see Methods) at the end of 2 h of incubation. Fig. 4 demonstrates the relationship between cAMP level and stimulation of GSH efflux or inhibition ofGSH synthesis mediated by CT and glucagon. At least a 45% increase in cAMP level was required to inhibit GSH synthesis, whereas a 25% increase in cAMP level led to near maximal stimulation of GSH efflux with no effect on synthesis.
Ca2" andprotein kinase C-dependentfactors. The effects of phenylephrine and vasopressin on GSH synthesis were assessed after 30 min of preincubation. Table III shows both agents inhibited GSH synthesis by -20%. Unlike cAMP-dependent factors, they did not affect GSH efflux.
Effects ofglucagon andphenylephrine on GSH synthesis in the perfused liver To confirm that the inhibitory effects of these hormones on GSH synthesis occur in models other than cultured hepatocytes, we measured GSH synthesis with or without hormone Role ofdifferent signal transduction pathways in the regulation ofGSH synthesis in cultured hepatocytes Both phenylephrine and vasopressin activate Gp protein which activates phospholipase C and ultimately activates protein kinase C (C-kinase) and raises cytosolic Ca2+ level. One important consequence ofraised cytosolic Ca2+ level is activation ofa Ca2+ binding protein, calmodulin. Factors that raise intracellular cAMP levels not only activate A-kinase but also may increase intracellular Ca2+ level (21) (22) (23) and possibly activate Ckinase. Therefore, any or all of these signal transduction pathways may be responsible for the effects of these hormones on GSH synthesis. The following series of experiments were designed to determine the role ofeach ofthese pathways and their interactions: The C-kinase pathway was directly assessed by PMA (500 nM), a C-kinase agonist which is also known to attenuate the glucagon-induced increase in cytoplasmic free Ca2' concentration (24) . Fig. 6 shows that treatment with PMA significantly inhibited GSH synthesis by 25%, whereas treatment with inactive phorbol (500 nM) was without effect. Staurosporine (10 nM), a C-kinase inhibitor (25) with Ki of 0.7 nM for C-kinase (per Kamiya Biochem Co.) completely blocked the effect of PMA (500 nM). Calmidazolium, a calmodulin inhibitor with IC50 in the micromolar range (26) , was used to examine the importance of the Ca2`-calmodulin pathway. Staurosporine (10 nM) or calmidazolium (1 MM) either alone or together had no effect on GSH synthesis but pretreatment with either agent partially blocked the effect of phenylephrine (0.1 mM). Combining staurosporine and calmidazolium completely prevented the inhibitory effect of phenylephrine. On the other hand, the same combination had no effect on glucagon-mediated inhibi- Having established that both cAMP and Ca2+/C-kinase signal transduction pathways independently lead to apparent inhibition of GSH synthesis, we considered the following possible mechanisms for inhibition of GSH synthesis in cultured cells: (a) decreased uptake of GSH precursors, methionine and cystine in cultured cells (cysteine in culture media is almost completely autoxidized to cystine) (27, 28) ; (b) decreased intracellular availability of L-cysteine, the rate-limiting factor in GSH synthesis; (c) decreased cofactor, ATP, needed for GSH synthesis; (d) decreased enzyme activity in the transsulfuration pathway leading to diminished conversion of methionine to cysteine; (e) increased hidden forms of GSH (those not measured by the recycling assay) such as GSH-cysteine mixed disulfides; and (f) decreased enzyme activity in GSH synthesis pathway.
To search for a preferential defect in GSH precursor uptake and the role ofthe transsulfuration pathway, we measured cell GSH levels after overnight incubation with DBcAMP (0.1 mM), PMA (500 nM) or phenylephrine (0.1 mM) in SAF media supplemented with either methionine (1 mM) or cystine (0.5 mM). Table IV shows that regardless of the type of GSH precursor present, cell GSH level fell to a similar degree after overnight treatment with each of these agents. This argues against inhibition of membrane transport since two entirely different transport systems take up the amino acids. This also argues against inhibition of transsulfuration pathway causing decreased GSH synthesis since cystine bypasses this pathway. To see if decreased intracellular availability of L-cysteine caused hormone-mediated inhibition, cultured hepatocytes were incubated overnight with glucagon (300 nM), phenylephrine (0.1 mM) or vehicle. Cellular cysteine level remained unchanged despite a significant fall in GSH compared to controls (Table V) . Liver cysteine levels were also measured at the end ofin situ liver perfusion experiments. There were no significant differences in liver cysteine levels after hormone treatments (control, 0.16±0.04; phenylephrine treated, 0.18±0.01; glucagon treated, 0.19±0.07 mM). Therefore, the inhibition ofGSH synthesis after hormone treatment was not due to limited availability of cysteine. This further excludes inhibitory effects on sulfur amino acid transport or transsulfuration as causing inhibition of cellular GSH synthesis.
To examine if depletion ofcell ATP level caused decreased GSH synthesis, GSH synthesis rates and cell ATP levels were measured after overnight incubation with DBcAMP (0.1 mM). Results from three cell preps showed significant inhibition of GSH synthesis after overnight incubation with DBcAMP (control 0.30±0.03 vs. DBcAMP 0.13±0.01 nmol/106 cells/min, P Results are in percentage of control±SEM of the number of cytosol preps (n). GSH synthesis rates were measured fluorometrically using mBCl by adding cytosol to the cuvette in the presence of the precursors for GSH: glutamate, glycine, and cysteine-DTT and cofactors, ATP, Mg2+ (see Methods).
* Addition of A-kinase was not necessary when fresh cytosol (prepared the same day) was used, but was necessary if the cytosol was stored > 5 d at -800C. Pretreatment of cytosol with A-kinase inhibitor for 5-7 min at 37°C was necessary to see any effect. Pretreatment of cytosol with DBcAMP and A-kinase did not result in further inhibition. Control GSH synthesis rates were 2.62±0.09 nmol/mg protein per mmi.
GSH synthesis, liver cytosol was added to the cuvette with only substrates for the second step in GSH synthesis ('y-glutamylcysteine, glycine, ATP, and Mg2"). Four cytosol preps showed addition of DBcAMP (1 mM) and A-kinase (200 ,g/ml) exerted no inhibitory effect under these conditions (GSH synthesis rates were 4.74±0.29 in controls and 4.59±0.46 nmol/mg protein per min in treatment groups). Therefore, GSH synthetase activity is not affected by DBcAMP and A-kinase. To ascertain whether DBcAMP treatment affects the Km or V. or both of y-glutamylcysteine synthetase, GSH synthesis rates in liver cytosols were measured with or without DBcAMP (1 mM) and A-kinase (200 .g/ml) while increasing the concentration of cysteine from 0.1 to 0.5 and 1.0 mM. Four cytosols preps showed that by increasing the concentration of cysteine from 0.1 to 0.5 mM, the rate of GSH synthesis increased by 40% (2.51±0.05 vs. 3.48±0.06 nmol/mg per min, respectively); 1.0 mM cysteine caused no further increase (3.50±0.14 nmol/ mg per min). Addition of DBcAMP and A-kinase exerted a significant (P < 0.05) inhibitory effect on GSH synthesis rate as compared to controls at each cysteine concentration examined (84±2% of control for 0.1 mM cysteine, 74±8% of control for 0.5 mM cysteine, and 84±1% of control for 1.0 mM cysteine). This suggests DBcAMP treatment affects the V,.
In vivo experiments with DBcAMP, phenylephrine, andglucagon. To examine if the effects of DBcAMP on y-glutamylcysteine synthetase could be reproduced in vivo, GSH synthesis rates of liver cytosols were measured fluorometrically using mBCl after rats were treated with DBcAMP and theophylline intraperitoneally (see Methods). Paired control liver cytosols (n = 4) exhibited a GSH synthesis rate of 2.82±0.06 nmol/mg protein per min, whereas the treatment group (n = 4) showed a GSH synthesis rate of 2.21±0.15 nmol/mg protein per min (78% of control, P < 0.02 vs. control by unpaired t test).
Similarly, GSH synthesis rates from precursors, cysteine (0.1 mM), glutamate (10 mM), and glycine (10 mM), measured in liver cytosols ofrats treated with intravenous phenylephrine (50 nmol/min) or glucagon (52 pmol/min) were significantly lower than paired controls. The phenylephrine group (n = 4) exhibited a GSH synthesis rate (2.05±0.16 nmol/mg protein per min) 72% of its controls (2.85±0.05 nmol/mg protein per min, P < 0.01 by unpaired t test) and the glucagon group (n = 4) exhibited a GSH synthesis rate (2.35±0.06 nmol/mg protein per min) 83% of control (2.83±0.16 nmol/mg protein per min, P < 0.05 by unpaired t test). However, the GSH synthesis rate from precursors for the second step of GSH synthesis, yglutamylcysteine and glycine, were not significantly different in the phenylephrine (4.16±0.67 nmol/mg protein per min) or glucagon-treated (3.36±0.39 nmol/mg protein per min) groups and their respective controls (5.06±0.36 and 4.06±0.64 nmol/ mg protein per min, respectively). Interestingly, in contrast to our previous results with glucagon revealing elevated plasma GSH levels at the dose employed in the present studies (10) , phenylephrine at the dose used (50 nmol/min) did not significantly change plasma GSH levels (not shown). However, before excluding an effect of phenylephrine in vivo on hepatic GSH efflux, turnover studies of plasma GSH will be required.
Plasma glucose level after 30 min ofglucagon infusion was 222±31% of baseline values (n = 4, P < 0.02 by paired t test), whereas it remained unchanged after 30 min ofinfusion in the paired controls. Phenylephrine infusion produced no change in plasma glucose levels. Plasma ALT levels did not significantly differ in the phenylephrine-treated group compared to its controls. Discussion GSH is synthesized from precursor amino kids in virtually all cells (31) . The liver plays a central role in the interorgan homeostasis of GSH and is unique in two aspects of GSH biosynthesis. First, it has the unique ability to convert methionine to cysteine through transsulfuration. Secondly, it is the major source of plasma GSH, exporting GSH into plasma and bile at a rate that matches nearly all of its biosynthesis. The synthesis of GSH from its constituent amino acids, glutamate, cysteine, and glycine, involves two ATP-requiring enzymatic steps: (1) y-glutamyl-L-cysteine formation from L-glutamate and L-cysteine and (2) GSH formation from y-glutamyl-L-cysteine and glycine. The first step is rate-limiting and catalyzed by y-glutamylcysteine synthetase, regulated physiologically by (a) feedback competitive inhibition by GSH and (b) the availability of its precursor, L-cysteine (1, 31, 32) . Cysteine availability depends on transsulfuration of methionine as well as sulfur amino acid transport.
The distinct membrane transport ofcysteine (ASC), cystine (Xc-), and methionine (L) have been well characterized in hepatocytes (27, 33) . Normally, cystine uptake is insignificant. However, upon culturing rat hepatocytes, cystine uptake activity is induced after a 12-h lag. This increase in transport activity of cystine depends on de novo synthesis of both RNA and protein (34) . This may be an adaptive response ofcultured cells since no detectable cysteine is in the culture medium (almost completely autoxidized). Thus, for the cultured hepatocyte model, the factors determining the rate of GSH synthesis are methionine and cystine uptake, transsulfuration, activities of the GSH synthetic enzymes and cellular GSH level (feedback inhibition).
Hepatic GSH levels fall after stressful conditions such as shock, fasting, inflammation, and exhaustive exercise (3) (4) (5) (6) (7) (8) (9) . Increased hepatic GSH efflux is at least partly responsible for the fall in liver GSH in fasting and exhaustive exercise (6, 7) . Higashi and co-workers (35) demonstrated almost 15 years ago that administration of dibutyryl-3',5'-cyclic AMP (DBcAMP) to rats caused -50% decrease in liver GSH (35) . Our own work (10) suggests cAMP stimulates sinusoidal GSH efflux while not affecting canalicular GSH effilux. Thus enhanced release of GSH may have caused part of the fall in liver GSH from DBcAMP. The only previous work to suggest hormonal regulation of GSH synthesis was that of Estrela and co-workers (36) who recently suggested that hormones which act through the Ca2+ and C-kinase-dependent signal transduction mechanisms, such as phenylephrine, stimulated GSH efflux and inhibited GSH synthesis in hepatocytes isolated after a 48-h fast. They suggested the mechanism of phenylephrine-mediated inhibition of GSH synthesis was by limiting the availability of glutamate since they noted 50% decrease in intracellular glutamate level after 1 h of treatment with phenylephrine and the inhibition was overcome when glutamine level was increased to 10 mM. However, the Km of y-glutamylcysteine synthetase for glutamate is -2 mM and ordinarily the intracellular glutamate level is almost 10-fold higher and probably does not play a regulatory role in GSH synthesis (27, 37, 38) . Specifically, Thor and colleagues (38) showed that omission of glutamate from the medium had no effect on either glutamate pool size or the rate of GSH synthesis. Therefore, the significance of their findings (36) is unclear and may pertain only to the marked perturbation of a 48-h fast. Thus, although there have been suggestions that hormones modulate hepatic GSH turnover, comparison of several classes of hormones which act through different signal transduction mechanisms and the steps in GSH homeostasis affected have not been previously examined.
Two major classes of hormones which affect hepatocyte metabolism and transport are divided on the basis of their signal transduction mechanisms: cAMP (glucagon) and Ca2+/diacylglycerol (vasopressin, phenylephrine). Increased cAMP activates A-kinase; increased cytosolic Ca2" activates a number of Ca2"-binding proteins; one of the most important is calmodulin which in turn activates specific calmodulin-dependent kinases; and diacylglycerol, along with Ca2", activates C-kinase. Factors that increase intracellular cAMP level have also been reported to increase intracellular Ca2" and possibly activate C-kinase as well (21) (22) (23) so that it is important to ascertain if cellular effects of cAMP are via A-kinase or via the Ca2+/Ckinase signaling pathways. These different signal transduction pathways modulate cell function through kinase-mediated phosphorylation of target proteins, sometimes in overlapping, redundant fashion.
In both cultured rat hepatocytes and perfused rat livers, cAMP, Ca2+, and protein kinase C-dependent factors all inhibited GSH synthesis. In addition, cAMP, but not Ca2" or protein kinase C-dependent factors also stimulated GSH efflux in cultured hepatocytes as we previously reported (10) . Furthermore, we found that there is a difference in the threshold of the two cAMP-mediated effects, namely, stimulation of GSH efflux and inhibition of GSH synthesis. At a lower cAMP threshold (25% increase in cAMP level over control), GSH efflux is stimulated; whereas at least a 45% increase in cAMP level was necessary to inhibit GSH synthesis. Thus, the effect of cAMP on effilux and synthesis of GSH could be dissociated, proving that the two effects are not interdependent. By using inhibitors of the different signal transduction pathways, we found that the effect of phenylephrine is mediated by both the C-kinase and Ca2+-calmodulin pathways. Thus, either the C-kinase inhibitor, staurosporine, or the calmodulin inhibitor, calmidazolium, only partially reversed the effect of phenylephrine but together completely prevented phenylephrine-mediated inhibition of GSH synthesis. The inhibitory effect ofglucagon, on the other hand, was not affected by pretreatment with both staurosporine and calmidazolium indicating that cAMP was not acting via Ca2+ or C-kinase to inhibit GSH synthesis indirectly. This suggests that A-kinase pathway mediates the inhibitory effect of glucagon on GSH synthesis.
As for the mechanism for inhibition of GSH synthesis in cultured cells, we considered limitation of sulfur amino acid precursors or cellular ATP which are necessary to support GSH synthesis versus direct inhibition of GSH synthetic enzymes.
Our data excluded limitation of cellular ATP as the mechanism. The maintenance ofcellular cysteine levels in the face of inhibition of GSH synthesis indicates that impaired sulfur amino acid transport or transsulfuration cannot explain the fall in GSH synthesis. Furthermore, we excluded oxidation or mixed disulfide formation of GSH leading to masking GSH levels. Finally, by using the mBCl technique to measure GSH synthesis rates in cell free conditions the inhibitory effect of cAMP via an A-kinase dependent mechanism was demonstrated directly under conditions of maximum precursor availability within the cytosol. The mechanism of cAMP and Akinase mediated inhibition is most likely phosphorylation of y-glutamylcysteine synthetase which leads to alteration in the V., of the enzyme.
Finally, the significance of our findings in the cultured cells and cell-free conditions were confirmed in in vivo models. Liver cytosol harvested from treated rats showed that both classes of hormones are capable ofexerting an inhibitory effect on GSH synthesis in vivo. These in vivo experiments also confirmed the most likely target to be regulation of the activity of -y-glutamylcysteine synthetase since GSH synthesis rates were similar to controls in the presence of precursors for the second step of GSH synthesis. In the case of glucagon, the dose employed approximates physiologic in producing a less than maximum glucose response according to our previous data (10) . With phenylephrine, however, more studies will be required to see ifit exerts an effect on GSH synthesis in vivo at doses which exhibit a physiologic effect on the liver.
In summary, we found cAMP-dependent factors both stimulate GSH efflux and inhibit GSH synthesis, whereas Ca2+/Ckinase-dependent factors inhibit GSH synthesis without affecting efflux. All three signal transduction pathways may lead to phosphorylation of GSH synthetic enzymes and account for the stress-induced fall in hepatic GSH. The physiological significance of hormonal regulation of hepatic GSH turnover, both increased GSH efflux and inhibition of GSH synthesis, remains a matter of speculation. Increased GSH export from the liver during stressful periods may be a mechanism for the liver to supply GSH to where it is needed. The hormonal dependence of GSH export may be part of a regulatory system to maintain the extracellular thiol redox balance in response to oxidant stress. GSH is also a source of cysteine. Therefore, increased export ofGSH during starvation may be a means for the liver to supply cysteine to the rest of the body. More difficult to reconcile is what purpose would decreased hepatic GSH synthesis serve in response to stress. Normally, the cellular concentration ofcysteine is very low since it is rapidly incorporated into GSH. Theoretically, this could be viewed as a buffering action to prevent accumulation of a potentially toxic amino acid since cysteine readily autoxidizes to cystine in the extracellular fluid, a process which generates toxic free radicals. A possible explanation is that normally the liver GSH level is high (5-10 mM) and during stressful periods hepatic synthesis of "acute phase" proteins may be more important than synthesis of GSH. By down-regulating GSH synthesis, cysteine can be channeled into other synthetic pathways. Many of the acute phase proteins are rich in cysteine, and provide important contributions in neutralizing the harmful consequences of tissue injury. At the same time, the GSH reservoir in the liver is so large that inhibition of synthesis does not lead to a fall to critically low levels which threaten hepatocyte defense. Furthermore, although the levels fall, supply to other tissues is maintained by the stimulation of effiux. At present, this teleologic explanation for down-regulation of hepatic GSH synthesis represents but one plausible possibility and further work will be required to define the molecular mechanism of down-regulation of GSH synthesis and its physiologic significance.
